Analysis Of Income And Expense [Abstract]

BerGenBio - Filing #2542730

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	354,000 NOK	—	—	—	389,000 NOK	—	—	—
Material income and expense [abstract]
Finance income (cost)	—	—	1,418,000 NOK	—	—	—	3,513,000 NOK	—	—	—
Operating expense	—	—	192,172,000 NOK	—	—	—	306,024,000 NOK	—	—	—
Expenses by nature [abstract]
Classes of employee benefits expense [abstract]
Short-term employee benefits expense [abstract]
Wages and salaries	—	—	52,428,000 NOK	—	—	—	66,143,000 NOK	—	—	—
Other employee expense	—	—	3,177,000 NOK	—	—	—	2,546,000 NOK	—	—	—
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation expense	—	—	223,000 NOK	—	—	—	883,000 NOK	—	—	—
Other expenses, by nature	—	—	136,345,000 NOK	—	—	—	236,451,000 NOK	—	—	—
Disclosure of attribution of expenses by nature to their function [text block]	—	—	—	—	—	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	0 NOK	0 NOK	1,167,000 NOK	1,167,000 NOK	0 NOK	0 NOK	484,000 NOK	484,000 NOK	0 NOK	0 NOK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	0 NOK	0 NOK	189,234,000 NOK	189,234,000 NOK	0 NOK	0 NOK	302,606,000 NOK	302,606,000 NOK	0 NOK	0 NOK